Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

INTRODUCTION: We evaluated the arginine‐depleting enzyme pegargiminase (ADI‐PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1‐deficient non‐squamous non‐small cell lung cancer (NSCLC) via a phase 1 dose‐expansion trial with exploratory biomarker analysis. METHODS: Sixty‐seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Szlosarek, Peter W., Wimalasingham, Akhila G., Phillips, Melissa M., Hall, Peter E., Chan, Pui Ying, Conibear, John, Lim, Louise, Rashid, Sukaina, Steele, Jeremy, Wells, Paula, Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Ellis, Stephen, Grantham, Marianne, Sheaff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495293/
https://www.ncbi.nlm.nih.gov/pubmed/34382365
http://dx.doi.org/10.1002/cam4.4196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495293/
https://www.ncbi.nlm.nih.gov/pubmed/34382365
http://dx.doi.org/10.1002/cam4.4196

Ejemplares similares